Gustavo Girotto
Hospital de Base
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gustavo Girotto as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:00 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT01345084 · Study Comparing Radiation Therapy and Chemotherapy With or Without NimotuzumabEurofarma Laboratorios S.A. · withdrawn · Carcinoma, Head and Neck Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:00 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.J Clin Oncol · 2020933 citationsRCR 38.9
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.Lancet Oncol · 2022286 citationsRCR 17.0
- 148 citationsRCR 12.7
- A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.Eur J Cancer · 201849 citationsRCR 1.6
- Linkage study and exome sequencing identify a BDP1 mutation associated with hereditary hearing loss.PLoS One · 201348 citationsRCR 1.3
- Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.J Clin Oncol · 202233 citationsRCR 1.9
- MYH9 related disease: four novel mutations of the tail domain of myosin-9 correlating with a mild clinical phenotype.Eur J Haematol · 201026 citationsRCR 0.6
- 25 citationsRCR 0.6
- Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.Oncologist · 20216 citationsRCR 0.3